That is, when evaluating anti-PD-1 therapy in the setting of platinum-refractory relapsed or metastatic HNSCC, CHECKMATE-141 failed to show a significant correlation between PD-L1 expression and tumor response or survival (51). The gene discussed is PDCD1; the disease is neoplasm.